The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
BUSINESS
Gilead’s JAK Med Hits Shelves in Japan; Launch Being Prepped for Oral Semaglutide, Rakuten Photoimmunotherapy
After a surprise setback in the US, Gilead Sciences launched its rheumatoid arthritis (RA) drug Jyseleca (filgotinib) in Japan on November 18 upon its reimbursement listing the same day, making it the country’s fifth oral JAK inhibitor for the treatment…
To read the full story
BUSINESS
- Meiji to Discontinue Sale of Kobayashi Kako Products after Biz Suspension
February 26, 2021
- Mylan EPD Offering EpiPen for Free to Prep for Possible Vaccine Reactions
February 26, 2021
- Daiichi Sankyo, France/Belgium Lymphoma Group to Collaborate on Valemetostat Trial
February 26, 2021
- MSD’s 9-Valent HPV Vaccine Now Available in Japan
February 25, 2021
- Ken Takeshita to Become Daiichi Sankyo’s Global R&D Head in April
February 25, 2021
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
By managing personal bias during the interview process, hiring managers can significantly improve their hit rate placing winning candidates. The trouble is, it’s easier said than done. It’s only natural we tend to like people we can relate to, people…